Research Paper Volume 15, Issue 4 pp 1074—1106

An immune-related prognostic signature associated with immune landscape and therapeutic responses in gastric cancer


Figure 9. The IRS in the role of immune checkpoint blocker treatment. (A) Kaplan-Meier survival curve of the high- versus low-risk group in the immunotherapy cohort (IMvigor210 cohort). (B) The proportion of immune response to immunotherapy in high versus low-risk group. (C) The tumor mutation burden in the immunotherapy cohort was compared among distinct risk groups. (D) Multivariate Cox regression analysis of the IRS with features in the immunotherapy cohort.